At C4 Therapeutics we are developing novel drugs based on the DEGRONIMID™ paradigm. These drugs are a new class of small molecules that direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. This paradigm shift in drug development will potentially provide new opportunities to target traditionally difficult diseases and resistance mechanisms.
C4 Therapeutics and Calico Enter Strategic Partnership
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif – March 23, 2017 – C4 Therapeutics (C4T) and Calico today announced a five-year collaboration to discover, develop, and commercialize therapies for treating diseases of aging, including cancer.
“We are thrilled to have Calico as partners in pioneering novel therapeutics based on targeted protein degradation,” said Andrew Phillips, President and Chief Scientific Officer of C4 Therapeutics. “Calico's leadership team has a long record of innovation and our combined efforts are aimed at bringing forward new options for patients affected by devastating diseases such as cancer.” read more...
C4 Therapeutics Announces World-Class Scientific Advisory Board
Cambridge, MA. – November 17, 2016 – C4 Therapeutics (C4T) today announced Ken Anderson, M.D., Nathanael Gray, Ph. D., Christopher Kirk, Ph. D. and Eric Fischer, Ph. D as the members of its Scientific Advisory Board (SAB).
“We are thrilled to have Ken, Nathanael, Chris, and Eric play an important role as our advisors at C4T,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Their world-renowned expertise in clinical oncology, drug discovery and development, and the basic-science of the ubiquitin-proteasome system will be invaluable as we both advance drug candidates toward the clinic and develop new tools and technologies that keep C4T at the cutting edge.” read more...
C4 Therapeutics Appoints Andrea Armstrong as CAO
Cambridge, MA. – September 22, 2016 – C4 Therapeutics (C4T) today announced that Andrea Armstrong has been promoted to Chief Administrative Officer. She joined C4T as a human resources consultant in January, 2016 and transitioned to full-time as the Senior Vice President of Human Resources in June, 2016. Ms. Armstrong has led the human resources function with a focus on talent acquisition efforts and will now also assume responsibility for facilities and laboratory operations, environmental health and safety, IT and office management, and internal communications.
“Andrea has been integral to the growth of C4T to this point,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “In addition to Andrea’s talents in human resources, her extensive organizational development and operational experience will bring much to our next phase of growth. I look forward to working with her in this expanded role.” read more...
What We Do